Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study

被引：0
|
作者：
Yasushi Goto
Nobuyuki Yamamoto
Elizabeth T. Masters
Hironori Kikkawa
Jack Mardekian
Robin Wiltshire
Kanae Togo
Yuichiro Ohe
机构：
[1] National Cancer Center Hospital,Department of Thoracic Oncology
[2] Wakayama Medical University,Department of Internal Medicine
[3] Health Economics and Outcomes Research,Medical Affairs, Oncology
[4] Pfizer Inc,Oncology Global Medical Affairs
[5] Pfizer Japan Inc,undefined
[6] Statistics,undefined
[7] Pfizer Inc.,undefined
[8] Pfizer Ltd,undefined
[9] Corporate Affairs,undefined
[10] Health and Value,undefined
[11] Pfizer Japan Inc.,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Advanced non-small cell lung cancer; Alectinib; Anaplastic lymphoma kinase; Crizotinib; Medical data vision; Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3311 / 3323
页数：12
相关论文
共 50 条
  • [41] Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer
    Gupta, Neeraj
    Hanley, Michael J.
    Sinha, Vikram
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3922 - 3923
  • [42] REAL-WORLD PROFILING OF NON-SMALL CELL LUNG CANCER PATIENTS IN JAPAN
    Takahashi, Chang E.
    Wakase, S.
    Ito, M.
    Taylor, T.
    VALUE IN HEALTH, 2022, 25 (01) : S121 - S122
  • [43] Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
    Ma, Di
    Hao, Xuezhi
    Wang, Yan
    Xing, Puyuan
    Li, Junling
    THORACIC CANCER, 2016, 7 (04) : 452 - 458
  • [44] Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer
    Matikas, Alexios
    Kentepozidis, Nikolaos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    CLINICAL LUNG CANCER, 2016, 17 (06) : 474 - 482
  • [45] Ensartinib in the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real-world, retrospective study
    Ding, Lieming
    Yuan, Xiaobin
    Wang, Yang
    Yang, Min
    Wu, Pengxiang
    Chen, Hui
    Yun, Yu
    Shen, Zhilin
    Ji, Dong
    Ma, Yongbin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (06) : 700 - 706
  • [46] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer
    Serritella, Anthony, V
    Bestvina, Christine M.
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 137 - 146
  • [48] The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
    Haili Qian
    Feng Gao
    Haijuan Wang
    Fei Ma
    BMC Cancer, 14
  • [49] Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase-positive non-small cell lung cancer: A case report
    Wang, Huan
    Wu, Zhenyan
    Shi, Guangqing
    Zhou, Jing
    Xiao, Zhenliang
    ONCOLOGY LETTERS, 2023, 26 (06)
  • [50] The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
    Qian, Haili
    Gao, Feng
    Wang, Haijuan
    Ma, Fei
    BMC CANCER, 2014, 14
12345